Age: 62.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: COVID-19 immunisation, Interchange of vaccine products, No adverse event
Clinical narrative: While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023; While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023), COVID-19 IMMUNISATION (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023) and NO ADVERSE EVENT (No adverse event) in a 62-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7642B) for COVID-19 prophylaxis.    Co-suspect product included non-company product FAMTOZINAMERAN, TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/5)) for an unknown indication.    No Medical History information was reported.   On 04-Jan-2023, the patient received dose of FAMTOZINAMERAN, TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/5)) (unknown route) 1 dosage form. On 09-Aug-2023, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023), COVID-19 IMMUNISATION (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023), COVID-19 IMMUNISATION (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for INTERCHANGE OF VACCINE PRODUCTS (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023) and COVID-19 IMMUNISATION (While inputting the information on the card, the HCP observed that the patient had received a previous Bivalent (later clarified that it was a Pfizer Bivalent) 04Jan2023).    Concomitant medication not reported.   Patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Dose 1 on 18 Mar 2021 with unknown lot number, Dose 2 on 15 Apr 2021 with batch number 025B21A and Dose 3 on 22 Dec 2021 with batch number 066H21A, Pfizer Bivalent dose on 04 Jan 2023 6J673A.  The patient was scheduled to receive the shingles vaccine but that was not given due to administration error.  Treatment medication not reported.